Oragenics Inc (NYSEAMERICAN:OGEN) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 877,585 shares, an increase of 13.0% from the August 15th total of 776,521 shares. Currently, 11.0% of the company’s shares are short sold. Based on an average trading volume of 486,169 shares, the short-interest ratio is presently 1.8 days.
Shares of NYSEAMERICAN:OGEN traded up $0.04 during trading on Wednesday, reaching $0.48. The company’s stock had a trading volume of 4,969,041 shares, compared to its average volume of 504,620. Oragenics has a 12 month low of $0.38 and a 12 month high of $6.80.
Oragenics (NYSEAMERICAN:OGEN) last announced its quarterly earnings results on Monday, August 13th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.03.
Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.